ArticleMolecular medicine (Cambridge, Mass.)2026
Divergent myeloid and lymphoid immune landscapes in HPV/p16 positive and HPV/p16 negative oropharyngeal squamous cell carcinomas and their lymph node metastases.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe tumor microenvironment of oropharyngeal squamous cell carcinoma (OPSCC) harbors diverse immune cell populations that influence tumor progression and patient outcome. MATERIALS: In 102 surgically treated OPSCCs, we determined HPV/p16 status by immunohistochemistry and RNA in situ hybridization. We analyzed mRNA transcripts using the PanCancer IO360 panel by NanoString. Multiplex immunohistochemistry/immunofluorescence was performed to characterize monocytic (M-MDSC, CD11b⁺CD14⁺HLA-DRlow/−CD15−) and polymorphonuclear myeloid derived suppressor cells (PMN-MDSC, CD11b⁺CD14−HLA-DRlow/−CD15+), M1-like (CD68⁺iNOS⁺) and M2-like macrophages (CD68⁺CD206⁺), B cells (CD20⁺), T helper cells (CD3⁺CD4⁺), and cytotoxic T cells (CD3⁺CD8⁺) in the tumor (TC) and stroma compartment (SC) of the primary tumor (PT) and the lymph node metastases (LM).
resultsTranscriptomic profiling revealed higher lymphoid compartment and antigen presentation scores in HPV/p16⁺ OPSCC (p = 0.002, p = 0.020, respectively), consistent with increased tumor-infiltrating lymphocytes (p = 0.025). HPV/p16– OPSCC exhibited higher myeloid compartment scores (p < 0.001). M2-like macrophages and M-MDSCs were significantly enriched in PT, while M1-like macrophages and PMN-MDSCs predominated in LM (p < 0.001 each). In HPV/p16 + OPSCC, M1-like macrophages, cytotoxic T and B cells were increased (p < 0.001, p < 0.001, p = 0.050, respectively), whereas MDSC frequencies were comparable between both HPV/p16 subgroups. Higher PMN-MDSC infiltration was correlated with poorer overall survival (OS, p = 0.050), while increased T helper, cytotoxic T, and B cell infiltration predicted improved OS (p = 0.009, p < 0.001, p = 0.005, respectively).
conclusionHPV/p16 + OPSCCs exhibit a lymphoid-dominant, antigen-presenting immune phenotype, whereas HPV/p16– tumors display a myeloid-dominated TME. Despite similar MDSC frequencies, transcriptional and spatial analyses suggest functional divergence of myeloid lineages and local immune differentiation between primary and metastatic sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.